HIV/AIDS HAART
Simplified maintenance therapy with atazanavir-ritonavir maintains virologic suppression
Published in AIDS Weekly, October 16th, 2006
According to a recent report from the United States, "The long-term adverse effects, expense, and difficulty of adherence to antiretroviral regimens have led to studies of simpler maintenance therapies.
"Maintenance therapy with ritonavir-boosted atazanavir alone is a possible option because of low pill burden, once-daily dosing, safety, and unique resistance profile."
S. Swindells and colleagues at the University of Nebraska Medical Center conducted a study to "assess whether simplified maintenance therapy with atazanavir-ritonavir alone...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2006-10-16)
More Articles from AIDS Weekly
- HIV/AIDS HAART
Rapid HAART scale-up at primary care sites in Zambia is feasible - HIV/AIDS HAART
Time to virologic failure similar in HIV/AIDS patients taking 3- versus 4-drug regimens - HIV/AIDS Opportunistic Infection
Risk factors for opportunistic infections in HIV-infected children on HAART identified - HIV/AIDS Pathogenesis
Differential HIV-1 replication influenced at the level of viral gene expression - Acute Diarrheal Illness
Enteroaggregative Escherichia coli is a cause of acute diarrheal illness - Alcohol Use
Heavy drinking can hasten the progression of the simian immunodeficiency virus disease - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
